Detalhe da pesquisa
1.
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast Cancer Res Treat
; 205(2): 267-279, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38453781
2.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol
; 170: 186-194, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706645
3.
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Gynecol Oncol
; 164(1): 18-26, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34696892
4.
Diagnostic chest X-rays and breast cancer risk among women with a hereditary predisposition to breast cancer unexplained by a BRCA1 or BRCA2 mutation.
Breast Cancer Res
; 23(1): 79, 2021 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34344426
5.
Gene- and pathway-level analyses of iCOGS variants highlight novel signaling pathways underlying familial breast cancer susceptibility.
Int J Cancer
; 148(8): 1895-1909, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368296
6.
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Br J Cancer
; 122(6): 759-765, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32001832
7.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178155
8.
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
Breast Cancer Res
; 21(1): 121, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727113
9.
Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
Int J Cancer
; 144(8): 1962-1974, 2019 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30303537
10.
Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Breast Cancer Res
; 20(1): 28, 2018 04 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29665859
11.
Impact of body composition on outcome in patients with early breast cancer.
Support Care Cancer
; 26(3): 861-868, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948392
12.
Assessment of Ki67 and uPA/PAI-1 expression in intermediate-risk early stage breast cancers.
BMC Cancer
; 17(1): 662, 2017 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28954632
13.
Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship.
Pharmacol Res
; 121: 138-144, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28473246
14.
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Cancer
; 122(19): 3032-40, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27315583
15.
GENESIS: a French national resource to study the missing heritability of breast cancer.
BMC Cancer
; 16: 13, 2016 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26758370
16.
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers.
Breast Cancer Res
; 14(2): R63, 2012 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-22513257
17.
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
Eur J Cancer
; 166: 300-308, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337692
18.
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study.
Adv Ther
; 39(6): 2731-2748, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35419649
19.
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
J Clin Oncol
; 40(32): 3699-3708, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35605174
20.
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.
JAMA Oncol
; 7(6): 853-861, 2021 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33885718